New studies show OXC-101 further improves conventional chemotherapy treatment in Acute Myelom Leukemia (AML)
According to a new study published online 28 Feb 2022 (Centio et al., "Inhibition of oxidized nucleotide sanitation by TH1579 and conventional chemotherapy cooperatively enhance oxidative DNA-damage and survival in AML", Mol Cancer Ther, doi: 10.1158/1535-7163.MCT-21-0185. Online ahead of print), OXC-101 (TH1579, karonudib) can inhibit AML progression as monotherapy but also boost standard chemotherapy response in AML pre-clinical models. AML is an aggressive blood cancer with estimated 25% 5-year survival, mainly due to primary resistance or relapse towards standard therapeutic regimens.